Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London · Delayed Price · Currency is GBP · Price in USD 396.66
+4.58 (1.17%)
At close: Aug 1, 2025
Chimerix Market Cap
Alnylam Pharmaceuticals has a market cap or net worth of 39.76 billion as of August 1, 2025. Its market cap has increased by 63.01% in one year.
Market Cap
39.76B
Enterprise Value
39.67B
Revenue
1.80B
Ranking
n/a
PE Ratio
n/a
Stock Price
$396.66
Market Cap Chart
Since May 28, 2004, Alnylam Pharmaceuticals's market cap has increased from 63.23M to 39.76B, an increase of 62,787.08%. That is a compound annual growth rate of 35.54%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 31, 2025 | 38.68B | 59.53% |
| Dec 31, 2024 | 24.24B | 28.56% |
| Dec 29, 2023 | 18.86B | -22.29% |
| Dec 30, 2022 | 24.27B | 62.00% |
| Dec 31, 2021 | 14.98B | 35.43% |
| Dec 31, 2020 | 11.06B | 14.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 178.30B |
| GSK plc | 59.04B |
| Haleon | 32.79B |
| Smith & Nephew | 10.33B |
| ConvaTec Group | 5.00B |
| Hikma Pharmaceuticals | 4.40B |
| HUTCHMED (China) | 2.34B |
| Oxford Nanopore Technologies | 1.94B |